Project Grant R00HL171838
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Augusta, GA 30912, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $766,920 to Augusta University Research Institute, Inc. to investigate the mechanisms linking improvements in skeletal muscle metabolism to vascular health in obesity. The research aims to determine how specific changes in skeletal muscle, such as the regulation of the CYP1B1 enzyme and sarcolipin, can protect vascular function in obese...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $768,198 to the Augusta University Research Institute, Inc. (dba Georgia Health Sciences) to conduct research on the function and transcriptional regulation of the Leiomodin1 (LMOD1) gene, which is associated with coronary artery disease (CAD). The research aims to elucidate the role of LMOD1 in maintaining normal vascular smooth muscle cell function...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $145,642 to Georgia Tech Research Corporation to engineer 3D pulmonary microtissue models to explore the role of fibroblast senescence in the development and progression of idiopathic pulmonary fibrosis (IPF). The project aims to: 1) develop an in vitro pulmonary microtissue model to assess differences in contractility, stiffness, cell...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) will support $2,282,280 in research over the period from August 2024 to May 2028. The grant will fund investigations into the role of HIV-derived proteins, CD4+ T cells, and the protein podocan-like protein 1 (PODNL1) in the development of pulmonary vascular disease (PVD) among...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $121,773 to the University of Arizona to investigate the role of the serum/glucocorticoid regulated kinase 1 (SGK1) in driving pathological cardiac hypertrophy. The research aims to determine if SGK1 is required for the development of cardiac hypertrophy and if impairing its degradation through the endoplasmic reticulum-associated degradation (ERAD)...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $752,541 R01 research project grant (CFDA 93.837 - Cardiovascular Diseases Research) to Dr. Alexander Hillel and Dr. Ramana Sidhaye at the Johns Hopkins University. The goal of this 4-year project, starting August 1, 2025, is to better understand how epithelial barrier dysfunction, specifically the loss of the E-cadherin protein, contributes to airway fibrosis in idiopathic subglottic stenosis (ISGS), a rare and life-threatening...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $740,317 to The Washington University in St. Louis to conduct research on the regulation of alveologenesis, the final phase of lung development, by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...